The global Viral Vector CTDMO Services market size is predicted to grow from US$ 262 million in 2025 to US$ 576 million in 2031; it is expected to grow at a CAGR of 14.0% from 2025 to 2031.
Viral vector CTDMO service refers to a business model that provides biopharmaceutical and biotechnology companies with comprehensive, highly flexible and customized viral vector R&D and production services. Among them, CTDMO is the abbreviation of Contract Testing, Development, and Manufacturing Organization. This service model integrates testing capabilities, process development capabilities and production platform capabilities, and can provide end-to-end services from viral vector construction, cell bank establishment, process development, scale-up, GMP (Good Manufacturing Practice) production to method development, quality inspection and release.
Key Features
- End-to-end services for viral vector construction and production.
- Customizable for biopharmaceutical and biotechnology companies.
- Integration of testing, development, and manufacturing.
Segmentation by Type
- Adeno-associated Viral
- Adenoviral
- Lentiviral
- Retroviral
Segmentation by Application
- Gene Therapy
- Cell Therapy
- Vaccine Development
Market by Region
- Americas
- APAC
- Europe
- Middle East & Africa
Company Coverage
- AGC Biologics
- Lonza
- Charles River Laboratories
- Thermo Fisher Scientific
- SK pharmteco
- Batavia Biosciences
- HALIX
- Catalent Biologics
- Oxford BioMedica
- Biovian
Key Questions Addressed in this Report
- What are the key trends affecting the market?
- How is the competitive landscape evolving?
- What are the growth opportunities for market participants?
Frequently Asked Questions
What is the USP of the report? expand_more
What are the key content of the report? expand_more
- Global Market Players
- Geopolitical regions
- Consumer Insights
- Technological advancement
- Historic and Future Analysis of the Market